1-3 of 3
Martin Sanabria
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study

Mark T Reding, María Teresa Alvarez Román, Martin Sanabria, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg
Journal: Blood
Blood (2022) 140 (Supplement 1): 5612–5614.
https://doi.org/10.1182/blood-2022-169159
Published: 2022
Journal Articles

Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study

Johannes Oldenburg, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, MD, Tadashi Matsushita, Karina Meijer, Sabine Friedl, Martin Sanabria, Mark Reding
Journal: Blood
Blood (2019) 134 (Supplement_1): 4943.
https://doi.org/10.1182/blood-2019-128140
Published: 2019
Journal Articles

Bay 81-8973 Prophylaxis Frequency and Long-Term Bleed Outcomes in the Leopold I Extension Study

Kapil Saxena, MD MS, Gautam Sajeev, ScD, Rajeev Ayyagari, PhD, Akanksha Dua, BA, Nikki Church, MD MBA, Martin Sanabria, MD, Olubunmi O. Afonja, MD MBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 1076.
https://doi.org/10.1182/blood.V130.Suppl_1.1076.1076
Published: 2017